October 25, 2024 10:36 AM EDT
News Briefing

En­Gene’s $60M PIPE; Ab­b­Vie to de­vel­op neu­ropsy­chi­atric drugs with Gedeon Richter

ENDPOINTS

Plus, news about Tec­ton­ic Ther­a­peu­tic, Mol­e­c­u­lar Part­ners and Ar­cus Bio­sciences:

En­Gene snags $60M: The Boston and Mon­tre­al gene ther­a­py biotech

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Rev­o­lu­tion Med­i­cines breaks ground in chal­leng­ing pan­cre­at­ic can­cer with two RAS drugs

Iterum wins ap­proval for new oral an­tibi­ot­ic for UTIs. Now it wants a part­ner

Post-Hoc: No­vo’s obe­si­ty en­e­mies

Chi­nook alums re­unite fol­low­ing ex­it to No­var­tis; The first board ap­point­ment for Re­cur­sion’s Chris Gib­son

Septer­na bags $288M up­sized IPO for GPCR drugs

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times